NO20072024L - Type 1 blokkeringsmidler for forebygging og behandling av psoriasis - Google Patents
Type 1 blokkeringsmidler for forebygging og behandling av psoriasisInfo
- Publication number
- NO20072024L NO20072024L NO20072024A NO20072024A NO20072024L NO 20072024 L NO20072024 L NO 20072024L NO 20072024 A NO20072024 A NO 20072024A NO 20072024 A NO20072024 A NO 20072024A NO 20072024 L NO20072024 L NO 20072024L
- Authority
- NO
- Norway
- Prior art keywords
- type
- psoriasis
- ifn
- prevention
- treatment
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title abstract 3
- 102000014150 Interferons Human genes 0.000 abstract 7
- 108010050904 Interferons Proteins 0.000 abstract 7
- 229940047124 interferons Drugs 0.000 abstract 5
- 239000002981 blocking agent Substances 0.000 abstract 2
- 229940079322 interferon Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04405628 | 2004-10-07 | ||
| PCT/CH2005/000566 WO2006037247A1 (fr) | 2004-10-07 | 2005-09-30 | Agents bloquants de l'interferon de type 1 dans la prevention et le traitement du psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072024L true NO20072024L (no) | 2007-04-26 |
Family
ID=35593663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072024A NO20072024L (no) | 2004-10-07 | 2007-04-20 | Type 1 blokkeringsmidler for forebygging og behandling av psoriasis |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20090155286A1 (fr) |
| EP (2) | EP1796722A1 (fr) |
| JP (1) | JP2008515819A (fr) |
| KR (1) | KR20070083809A (fr) |
| CN (1) | CN101056654A (fr) |
| AU (1) | AU2005291741B2 (fr) |
| BR (1) | BRPI0516470A (fr) |
| CA (1) | CA2582471A1 (fr) |
| IL (1) | IL182087A0 (fr) |
| MX (1) | MX2007003809A (fr) |
| NO (1) | NO20072024L (fr) |
| NZ (1) | NZ554065A (fr) |
| RU (2) | RU2007116988A (fr) |
| WO (1) | WO2006037247A1 (fr) |
| ZA (1) | ZA200702794B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2236156A3 (fr) | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Méthods pour traiter et diagnoser le Psoriasis |
| US7888481B2 (en) | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
| CA2597265C (fr) | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anticorps monoclonaux anti-interferon alpha et procedes d'utilisation |
| EP2279207B1 (fr) | 2008-05-07 | 2015-09-09 | Argos Therapeutics, Inc. | Anticorps humanisés contre l'interféron-alpha humain |
| FR2968561B1 (fr) | 2010-12-13 | 2013-08-09 | Lfb Biotechnologies | Utilisation d'un anticorps dirige contre une proteine membranaire |
| EP2623978A1 (fr) | 2012-02-03 | 2013-08-07 | Charité - Universitätsmedizin Berlin | Sous-ensembles de lymphocyte T CD8+ en tant que marqueurs pour la prédiction de la guérison de fractures retardées |
| CN103319608B (zh) * | 2013-07-01 | 2014-08-27 | 江苏众红生物工程创药研究院有限公司 | 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法 |
| CN106029874B (zh) | 2013-12-16 | 2020-09-15 | 北卡罗来纳-查佩尔山大学 | 浆细胞样树突状细胞的耗竭 |
| RU2016129744A (ru) * | 2013-12-24 | 2018-01-30 | Астеллас Фарма Инк. | Новое антитело против bdca-2 человека |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| JP7374091B2 (ja) | 2017-08-22 | 2023-11-06 | サナバイオ， エルエルシー | 可溶性インターフェロン受容体およびその使用 |
| JP7406254B2 (ja) * | 2018-06-01 | 2023-12-27 | アイエルシー セラピューティクス リミテッド | 疾患の治療に関する組成物および方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4423147A (en) * | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
| US4605394A (en) * | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
| US4824432A (en) * | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
| US4362155A (en) * | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
| DE3211263A1 (de) * | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
| EP0139676B1 (fr) * | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production et caracterisation d'anticorps d'hybridomes diriges specifiquement contre un/des determinant(s) commun(s) present(s) parmi des proteines en relation etroite mais distinctes |
| GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| FR2560212B1 (fr) * | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
| EP0563487A1 (fr) * | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Anticorps monoclonaux contre le récepteur d'interféron avec une activité contre l'interféron du type I |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| AUPP670698A0 (en) * | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
| DE19919149A1 (de) | 1999-04-27 | 2000-11-16 | Wieser Raimund J | Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere |
| JP5007007B2 (ja) * | 1999-11-15 | 2012-08-22 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞 |
| GB0001710D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
| GB0001712D0 (en) * | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
| US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| EP2236156A3 (fr) * | 2001-01-09 | 2011-01-05 | Baylor Research Institute | Méthods pour traiter et diagnoser le Psoriasis |
| US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| EA013677B1 (ru) * | 2002-11-15 | 2010-06-30 | Генмаб А/С | Человеческие моноклональные антитела против cd25 и их применение |
| DK1711207T3 (da) * | 2003-12-10 | 2013-03-11 | Medarex Inc | Interferon-alpha-antistoffer og anvendelse heraf |
| CA2597265C (fr) * | 2005-02-10 | 2015-03-24 | Baylor Research Institute | Anticorps monoclonaux anti-interferon alpha et procedes d'utilisation |
| US7888481B2 (en) * | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
-
2005
- 2005-09-30 NZ NZ554065A patent/NZ554065A/en not_active IP Right Cessation
- 2005-09-30 RU RU2007116988/15A patent/RU2007116988A/ru unknown
- 2005-09-30 EP EP05786466A patent/EP1796722A1/fr not_active Withdrawn
- 2005-09-30 CA CA002582471A patent/CA2582471A1/fr not_active Abandoned
- 2005-09-30 CN CNA2005800339202A patent/CN101056654A/zh active Pending
- 2005-09-30 JP JP2007534986A patent/JP2008515819A/ja active Pending
- 2005-09-30 BR BRPI0516470-2A patent/BRPI0516470A/pt not_active IP Right Cessation
- 2005-09-30 KR KR1020077009475A patent/KR20070083809A/ko not_active Ceased
- 2005-09-30 MX MX2007003809A patent/MX2007003809A/es not_active Application Discontinuation
- 2005-09-30 EP EP10180347A patent/EP2286835A1/fr not_active Withdrawn
- 2005-09-30 US US11/664,869 patent/US20090155286A1/en not_active Abandoned
- 2005-09-30 WO PCT/CH2005/000566 patent/WO2006037247A1/fr not_active Ceased
- 2005-09-30 AU AU2005291741A patent/AU2005291741B2/en not_active Ceased
-
2007
- 2007-03-21 IL IL182087A patent/IL182087A0/en unknown
- 2007-04-03 ZA ZA200702794A patent/ZA200702794B/en unknown
- 2007-04-20 NO NO20072024A patent/NO20072024L/no not_active Application Discontinuation
-
2010
- 2010-11-12 RU RU2010146161/15A patent/RU2010146161A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005291741A1 (en) | 2006-04-13 |
| WO2006037247A1 (fr) | 2006-04-13 |
| ZA200702794B (en) | 2008-06-25 |
| BRPI0516470A (pt) | 2008-09-09 |
| KR20070083809A (ko) | 2007-08-24 |
| IL182087A0 (en) | 2007-07-24 |
| RU2007116988A (ru) | 2008-11-20 |
| AU2005291741B2 (en) | 2011-11-24 |
| JP2008515819A (ja) | 2008-05-15 |
| EP2286835A1 (fr) | 2011-02-23 |
| EP1796722A1 (fr) | 2007-06-20 |
| US20090155286A1 (en) | 2009-06-18 |
| CN101056654A (zh) | 2007-10-17 |
| CA2582471A1 (fr) | 2006-04-13 |
| NZ554065A (en) | 2010-12-24 |
| RU2010146161A (ru) | 2012-05-20 |
| MX2007003809A (es) | 2007-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072024L (no) | Type 1 blokkeringsmidler for forebygging og behandling av psoriasis | |
| NO20084931L (no) | Farmasoytiske sammensetninger | |
| ATE510841T1 (de) | Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase | |
| NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
| GT200100183A (es) | Derivados de quinolina y quinazolina. | |
| BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
| NO20082125L (no) | Substituerte benzokondenserte derivater og deres anvendelse som vanilloidreseptorligander | |
| NO20082311L (no) | Terapeutisk middel for hjertesykdom | |
| NO20080487L (no) | Rekominant interferona2 (IFNa2) mutanter | |
| NO20052512L (no) | Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander | |
| NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
| NZ598061A (en) | Stat3/5 activation inhibitor | |
| UA96308C2 (ru) | Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение | |
| BR112012010762A2 (pt) | inibidores de prolil hidroxilalse | |
| NO20072608L (no) | Biaryloksymetylarenkarboksylsyrer | |
| GB2453068A (en) | Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells | |
| NO20074084L (no) | Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikamenter og medikamenter inneholdende disse | |
| NO20054405L (no) | Kjemokinreseptor-binende heterosykel | |
| UY28080A1 (es) | Isómeros posicionales del ifn peg alfa 2a | |
| ATE550032T1 (de) | Verwendung von glp-1, exendin und agonisten davon zur verzögerung oder verhinderung von kardialer remodellierung | |
| EP3929182A4 (fr) | Inhibiteur de kinase multi-cibles, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation | |
| DK1699459T3 (da) | Fremgangsmåde til behandling af multipel sclerose | |
| BR112021026531A2 (pt) | Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2 | |
| ATE413392T1 (de) | Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren | |
| DE502005008373D1 (de) | Polymorphismen im nod2/card15 gen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |